Skip to content
All resources

GLP-1 and metabolic

GLP-1 Muscle Loss: What Body-Composition Studies Actually Measured

AM

By

· 11 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. Why is GLP-1 muscle loss a concern?
  2. What is the difference between lean mass and muscle?
  3. What did the tirzepatide body-composition substudies find?
  4. What about semaglutide and retatrutide?
  5. Why is the proportion of lean mass lost debated?
  6. What muscle-preserving drugs are being tested alongside GLP-1 drugs?
  7. What does this mean for reading the trials?
  8. Frequently asked questions

People who lose weight on GLP-1-based drugs lose lean mass as well as fat. In the SURMOUNT-1 DXA substudy of tirzepatide, about 75% of the weight lost was fat and 25% lean mass, in the same proportion as on placebo. A 2026 systematic review found a median of about 28% of weight lost from muscle-related measures across incretin trials. But DXA "lean mass" is not muscle, and few studies measured strength or function. Whether the loss is harmful remains unsettled.

Skeletal muscle fibre bundles beside fat tissue, in the style of a micrograph
Illustration in the style of a micrograph, not experimental data: muscle and fat, the two compartments body-composition scans separate.

Why is GLP-1 muscle loss a concern?

Any substantial weight loss removes some lean tissue along with fat. The concern with incretin-based drugs is scale and speed. Tirzepatide, semaglutide and investigational agents like retatrutide, which differ in the receptors they act at as the receptor guide explains, produce weight reductions that used to be possible only with surgery. If a fixed share of that loss is muscle, the absolute amount can be large, and skeletal muscle matters for strength, mobility, glucose disposal and resilience in older age.

The question has three parts that are often run together. How much lean mass is lost? How much of that is actually muscle? And does the loss change strength, function or health? The evidence is strongest on the first, weaker on the second and thin on the third.

What is the difference between lean mass and muscle?

Most trial substudies use dual-energy X-ray absorptiometry (DXA), which divides the body into fat, bone mineral and "lean soft tissue". Lean soft tissue is everything else: skeletal muscle, but also organs, skin, connective tissue, blood, and the water and glycogen held in all of them. Weight loss shrinks several of these at once. The liver loses fat and glycogen, total body water falls, and fluid shifts can register as lean mass lost without any muscle protein changing.

Magnetic resonance imaging (MRI) and computed tomography can measure muscle volume directly, usually in the thigh, and can also measure fat infiltrating the muscle, which affects muscle quality. A systematic review by Batsis and colleagues used different expected benchmarks for the two methods, about 25% of weight lost for DXA lean tissue and about 15% for MRI or CT muscle, because the two methods measure different things.

MethodWhat it measuresWhat it misses
DXAFat, bone and lean soft tissue across the whole bodyCannot separate muscle from organs and water
MRI or CTMuscle volume and fat infiltration in a region, usually the thighUsually one region; small samples
Bioelectrical impedanceEstimates fat-free mass from electrical conductionSensitive to hydration; least precise
Strength and function testsGrip strength, sit-to-stand, walking speedRarely included in incretin trials

What did the tirzepatide body-composition substudies find?

SURMOUNT-1 DXA. Look and colleagues reported DXA at baseline and week 72 for 160 of SURMOUNT-1's 2,539 participants, 73% of them female. With tirzepatide, body weight fell 21.3%, fat mass 33.9% and lean mass 10.9%. With placebo, the figures were 5.3%, 8.2% and 2.6%. In both arms, about 75% of the weight lost was fat and 25% lean, and those proportions held across most subgroups by sex, age and amount lost. So tirzepatide caused more lean loss in absolute terms because it caused more weight loss, not because it shifted the composition of the loss.

SURPASS-3 MRI. Sattar and colleagues analysed thigh MRI in 246 people with type 2 diabetes over 52 weeks, comparing tirzepatide with insulin degludec. With tirzepatide, thigh muscle volume fell by 0.64 L and muscle fat infiltration fell by 0.36 percentage points. Using UK Biobank data, the authors estimated how much muscle volume would be expected to change for the amount of weight lost. The observed loss matched that expectation, while the fall in fat infiltration was larger than expected. It was a post hoc analysis of an open-label, Lilly-funded trial.

What about semaglutide and retatrutide?

Semaglutide (STEP UP MRI). Hjelmesæth and colleagues reported MRI body composition from the STEP UP trial. Of 1,407 participants, only 55 had a valid baseline scan and were included: 49 on semaglutide and 6 on placebo. Against placebo, adipose tissue fell by 11.1 L and thigh muscle fat infiltration by 0.92 percentage points. Thigh muscle volume fell by 1.1 L, but that difference was not statistically significant (p = 0.07), which is unsurprising with a placebo group of six. Sit-to-stand repetitions went from a mean of 13 at baseline to 15 at week 72, one of the few functional measures reported anywhere in this literature.

Retatrutide (phase 2 DXA). Coskun and colleagues reported a DXA substudy of retatrutide's phase 2 diabetes trial. Of 189 participants enrolled in the substudy, 103 completed treatment with both scans. Fat mass fell by up to 26.1% across retatrutide groups, against 4.5% on placebo. The authors report that the share of weight lost as lean mass was similar to other obesity treatments. Retatrutide is investigational and approved nowhere; the retatrutide overview covers the rest of its programme. Body composition is also missing from the abstract of eloralintide's phase 2 trial, which reports total weight only.

Notice the attrition. In each substudy only a fraction of the parent trial was scanned, and fewer still were scanned twice. Missing scans are not random: people who stop treatment early are more likely to miss the final scan.

Why is the proportion of lean mass lost debated?

Because the same data support different framings.

Proportion vs absolute amount. A meta-analysis by Eisa and Barood pooled 20 trials and found lean mass made up 25% to 39% of weight lost with incretin drugs: 35.2% for semaglutide and 25.4% for tirzepatide. Lifestyle interventions came to 26.2%, a comparable share. Lifestyle plus resistance training came to 17.5%. On that reading, the drugs behave like any other way of losing weight. But a comparable share of a much larger loss is a larger absolute loss, and absolute muscle mass is what matters for strength.

Relative composition can improve while mass falls. Laverde and colleagues found lean mass as a percentage of body weight rose with GLP-1 receptor agonists, because fat fell faster, even as absolute lean mass fell. Both statements are true. Which one is reported depends on the author's argument.

Heterogeneity is large. Batsis and colleagues reviewed 35 randomised trials. The median share of weight lost from muscle-related measures was 28.3%, but the interquartile range ran from 15.9% to 39.9%. About two-thirds of incretin interventions exceeded the expected benchmarks, as did nearly half of the non-drug interventions that produced weight loss. Only 10 of the 35 trials had prespecified body composition as a primary outcome, and none reported objective physical function. The review was too heterogeneous to pool.

Muscle quality is a separate axis. Both MRI studies found fat infiltration in muscle fell. Less fat in the muscle may offset some loss of volume, but whether it does, in terms of strength or function, has not been tested.

What muscle-preserving drugs are being tested alongside GLP-1 drugs?

Several investigational drugs aim to block myostatin or activin signalling, which normally restrains muscle growth. None is approved for preserving muscle during weight loss.

Bimagrumab is an antibody against type II activin receptors. In a 2021 phase 2 trial in 75 adults with type 2 diabetes and obesity, it reduced fat mass by 20.5% and increased lean mass by 3.6% over 48 weeks, against −0.5% and −0.8% on placebo. The BELIEVE trial then randomised 507 adults with obesity to bimagrumab, semaglutide, both, or placebo. At 48 weeks, mean weight change was −17.8 kg with the high-level combination, −14.2 kg with semaglutide alone, −9.3 kg with bimagrumab alone and −3.3 kg with placebo. Muscle spasms, diarrhoea and acne were common with bimagrumab. Its primary endpoint was body weight, and the abstract does not report body-composition results. A trial combining bimagrumab with tirzepatide is registered (NCT06643728).

Apitegromab selectively blocks myostatin activation. In the 102-participant EMBRAZE trial, people on tirzepatide plus apitegromab lost 1.9 kg less lean mass at 24 weeks than those on tirzepatide plus placebo, with similar total weight loss. The result is reported with an 80% confidence interval rather than the usual 95%, typical of proof-of-concept work, and the trial ran 24 weeks.

Others registered. COURAGE tests trevogrumab, with or without garetosmab, alongside semaglutide in about 1,005 participants (NCT06299098). QUALITY tested enobosarm, a selective androgen receptor modulator, in 168 people taking a GLP-1 drug (NCT06282458). No peer-reviewed results from either were found on PubMed by October 2026.

These mid-stage trials measure lean mass, a surrogate. Whether preserving it translates into better strength, function or health is still unanswered. The study design guide explains why a surrogate endpoint is a hypothesis about an outcome, not the outcome itself.

What does this mean for reading the trials?

The weight figures in the headline results of the tirzepatide vs semaglutide trials and the retatrutide phase 3 trials are not fat figures. Roughly a quarter to a third of each kilogram lost was lean tissue in the substudies that measured it. Some of that is muscle and some is not. Trial safety tables do not usually list muscle loss as an adverse event; the tirzepatide side-effects article covers what they do record.

Supplied here for laboratory use: Tirzepatide and Retatrutide. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Tirzepatide and semaglutide are authorised medicines in Canada; retatrutide and the muscle-targeting agents above are investigational. The studies describe trial participants given licensed or investigational products, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

How much muscle do you lose on GLP-1 drugs? Trials mostly measure lean mass, not muscle. In the SURMOUNT-1 DXA substudy, lean mass made up about 25% of weight lost with tirzepatide, the same share as on placebo. A meta-analysis found 25% to 39% across incretin drugs. MRI studies of thigh muscle found volume losses broadly in line with the amount of weight lost.

Is lean mass the same as muscle? No. DXA lean mass includes skeletal muscle plus organs, skin, connective tissue, blood and the water and glycogen they hold. Some lean mass lost during weight loss is water and organ tissue, especially liver. MRI and CT can measure muscle volume directly, but they are used in fewer, smaller studies.

Do GLP-1 drugs cause more muscle loss than dieting? In proportion to weight lost, apparently not. A meta-analysis found lean mass made up 26.2% of weight lost with lifestyle intervention, comparable to tirzepatide's 25.4%, while semaglutide's figure was 35.2%. Because the drugs produce more weight loss, the absolute lean loss is larger. Resistance training was associated with the smallest share.

Did the trials measure strength or physical function? Rarely. A systematic review of 35 incretin trials with body-composition data found none that reported objective physical function. A later MRI analysis from the semaglutide STEP UP trial reported sit-to-stand repetitions rising from 13 to 15. Function is the outcome that matters most and the one measured least.

Is bimagrumab approved to prevent muscle loss? No. Bimagrumab, apitegromab, trevogrumab, garetosmab and enobosarm are investigational for this use. Phase 2 trials have measured body weight or lean mass when they are combined with semaglutide or tirzepatide. None has shown improved strength, function or long-term outcomes, and none is authorised for preserving muscle.

Selected Research References

  1. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes, Obesity and Metabolism. 2025;27(5):2720-2729. pubmed.ncbi.nlm.nih.gov/39996356
  2. Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. 2025;13(6):482-493. pubmed.ncbi.nlm.nih.gov/40318682
  3. Hjelmesæth J, Bhat S, Garvey WT, et al. Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, Obesity and Metabolism. 2026. pubmed.ncbi.nlm.nih.gov/42764399
  4. Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. 2025;13(8):674-684. pubmed.ncbi.nlm.nih.gov/40609566
  5. Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Annals of Internal Medicine. 2026;179(7):996-1013. pubmed.ncbi.nlm.nih.gov/41996180
  6. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026;28(6):4818-4827. pubmed.ncbi.nlm.nih.gov/41877354
  7. Laverde LP, Muñoz-Velandia OM, Alfonso D, Gómez Medina AM. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs). International Journal of Obesity. 2026;50(8):1638-1646. pubmed.ncbi.nlm.nih.gov/42321502
  8. Heymsfield SB, Coleman LA, Miller R, et al. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Network Open. 2021;4(1):e2033457. pubmed.ncbi.nlm.nih.gov/33439265
  9. Heymsfield SB, Aronne LJ, Montgomery P, et al.; BELIEVE trial investigators. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine. 2026;32(3):869-882. pubmed.ncbi.nlm.nih.gov/41772149
  10. Pratley RE, Denham DS, Trivedi R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature Medicine. 2026;32(7):2673-2678. pubmed.ncbi.nlm.nih.gov/42260100

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.